Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.

International journal of oncology - 1 Mar 2016

Neil Jayson, Shannon Craig, Mohan Avinash, Laurent Dimitri, Murali Raj, Jhanwar-Uniyal Meena

Abstract excerpt

The PI3K-AKT-mTOR signaling axis is central to the transformed phenotype of glioblastoma (GBM) cells, due to frequent loss of tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10). The mechanistic target of rapamycin (mTOR) kinase is present in two cellular multi-protein complexes, mTORC1 and mTORC2, which have distinct subunit composition, substrates and mechanisms of action. Targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotaxis
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mechanistic Target of Rapamycin Complex 2

Share to Multiprotein Complexes

Share to Purines

Share to S Phase

Share to Sirolimus

Source

Identifiers

PMID: 26719046
DOI: 10.3892/ijo.2015.3311

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.PMID 26719046Read ↗

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKTSemantic proximity Read ↗

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical EvidenceSemantic proximity Read ↗

mTOR-Dependent Cell Proliferation in the BrainSemantic proximity Read ↗

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsSemantic proximity Read ↗

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.Semantic proximity Read ↗

mTOR signaling in glioblastoma: lessons learned from bench to bedsideSemantic proximity Read ↗

Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude MiceSemantic proximity Read ↗

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.Semantic proximity Read ↗

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerSemantic proximity Read ↗

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Semantic proximity Read ↗

Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).Semantic proximity Read ↗

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.